Algemeen Ziekenhuis Delta

At Algemeen Ziekenhuis Delta in Roeselare, gastroenterology research includes a strong focus on Crohn’s disease, ulcerative colitis, and broader inflammatory bowel disease. These studies are designed to improve symptom control, support long-term disease management, and evaluate new treatment approaches for patients with chronic intestinal inflammation.

• Testing new therapies for active Crohn’s disease and ulcerative colitis
• Evaluating maintenance strategies to help keep bowel disease under control
• Studying ways to reduce postoperative recurrence and improve long-term outcomes

This area reflects a major commitment to improving both day-to-day care and durable remission in digestive system diseases.

The site is highly active in cancer research, especially for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancers, and blood cancers such as acute myeloid leukemia, lymphoma, and multiple myeloma. These trials aim to assess new treatment combinations, improve survival, and expand options for both newly diagnosed and relapsed disease.

• Evaluating novel treatments for advanced solid tumors and metastatic disease
• Studying immune-based and targeted approaches in lymphoma, leukemia, and myeloma
• Comparing emerging therapies with current standard treatments

Across these studies, Algemeen Ziekenhuis Delta contributes to research aimed at making cancer care more effective and more precise.

A large part of the trial portfolio centers on lung cancer, including advanced non-small cell lung cancer, small cell lung cancer, and mutation-defined subtypes such as EGFR, MET, and KRAS G12C disease. Research also includes chronic obstructive pulmonary disease, idiopathic pulmonary fibrosis, and severe lung infections, with the goal of improving treatment effectiveness and clinical outcomes.

• Testing targeted and immune-based therapies for advanced lung cancer
• Studying new options for small cell lung cancer and early-stage disease
• Evaluating treatments for serious respiratory conditions and infections

These studies address both common and aggressive lung diseases, reflecting a broad respiratory medicine research focus.

Clinical trials at this hospital also cover cardiovascular disease, heart failure, hypertension, atherosclerotic disease, chronic kidney disease, IgA nephropathy, diabetes, obesity, and liver-related metabolic disorders such as MASH and NASH. The purpose is to better prevent complications, slow disease progression, and improve long-term organ health.

• Assessing therapies for kidney disease and proteinuria
• Studying new approaches for cardiovascular risk and heart failure
• Evaluating treatments for metabolic dysfunction and related liver disease

This research area combines prevention and treatment studies across several linked chronic conditions.

The trial landscape includes important work in rheumatoid arthritis, multiple sclerosis, vasculitis, immune thrombocytopenia, and transplant-related immune complications such as graft-versus-host disease. These studies focus on improving immune control, reducing disease activity, and supporting safer long-term management.

• Testing therapies for autoimmune disorders and immune-mediated inflammation
• Evaluating treatments for multiple sclerosis and other neurologic immune diseases
• Studying approaches for transplant complications and immune recovery

The work in this area highlights a strong interest in refining care for complex immune system diseases.

Beyond disease-specific treatment studies, Algemeen Ziekenhuis Delta is involved in trials that examine diagnostic techniques, symptom management, and supportive interventions. Examples include research on endoscopic assessment, pain-related care, and treatment support in difficult-to-manage conditions.

• Improving diagnostic evaluation in gastrointestinal care
• Studying symptom-focused interventions for chronic conditions
• Supporting better treatment decisions through clinical assessment research

This part of the portfolio shows that the site’s research extends beyond new medicines to include practical ways of improving patient care.